Insulin degludec

Generic Name
Insulin degludec
Brand Names
Ryzodeg, Tresiba, Xultophy
Drug Type
Biotech
Chemical Formula
-
CAS Number
844439-96-9
Unique Ingredient Identifier
54Q18076QB
Background

Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...

Indication

Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Associated Conditions
Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

First Posted Date
2010-02-15
Last Posted Date
2017-03-06
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
460
Registration Number
NCT01068678
Locations
🇬🇧

Novo Nordisk Investigational Site, Watford, United Kingdom

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

First Posted Date
2010-02-01
Last Posted Date
2017-03-30
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
435
Registration Number
NCT01059799
Locations
🇹🇭

Novo Nordisk Investigational Site, Songkla, Thailand

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

First Posted Date
2010-01-11
Last Posted Date
2017-03-03
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
458
Registration Number
NCT01046110
Locations
🇹🇷

Novo Nordisk Investigational Site, Izmir, Turkey

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

First Posted Date
2010-01-06
Last Posted Date
2017-01-23
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
63
Registration Number
NCT01043510
Locations
🇺🇸

Novo Nordisk Investigational Site, Chula Vista, California, United States

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

First Posted Date
2009-12-14
Last Posted Date
2017-01-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
39
Registration Number
NCT01030926
Locations
🇩🇪

Novo Nordisk Investigational Site, Hannover, Germany

A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

Phase 1
Completed
Conditions
Diabetes
Healthy
Interventions
Drug: insulin degludec
First Posted Date
2009-11-01
Last Posted Date
2017-01-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
32
Registration Number
NCT01006057
Locations
🇭🇺

Novo Nordisk Investigational Site, Budapest, Hungary

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes

First Posted Date
2009-11-01
Last Posted Date
2017-02-09
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
687
Registration Number
NCT01006291
Locations
🇬🇧

Novo Nordisk Investigational Site, Swansea, United Kingdom

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

First Posted Date
2009-10-27
Last Posted Date
2017-01-20
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
28
Registration Number
NCT01002768
Locations
🇦🇹

Novo Nordisk Investigational Site, Graz, Austria

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

First Posted Date
2009-10-09
Last Posted Date
2013-11-27
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
27
Registration Number
NCT00992537

Safety and Tolerability of NN9068 in Healthy Male Volunteers

First Posted Date
2009-09-23
Last Posted Date
2017-02-08
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
24
Registration Number
NCT00983021
Locations
🇩🇪

Novo Nordisk Investigational Site, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy